Login / Signup

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.

Gils RoexMarijke TimmersKristien WoutersDiana Campillo-DavoDonovan FlumensWilfried SchroyensYiwei ChuZwi N BernemanEva LionFeifei LuoSébastien Anguille
Published in: Journal of hematology & oncology (2020)
Although considerable toxicity was observed, BCMA-targeted CAR-T-cell therapy is highly efficacious even in advanced multiple myeloma. Subgroup analysis confirmed the anticipated inter-study heterogeneity and identified potential factors contributing to safety and efficacy. The results of this meta-analysis may assist the future design of CAR-T-cell studies and lead to optimized BCMA CAR-T-cell products.
Keyphrases
  • cell therapy
  • multiple myeloma
  • systematic review
  • stem cells
  • mesenchymal stem cells
  • case control
  • oxidative stress
  • meta analyses
  • cancer therapy
  • current status
  • clinical trial
  • bone marrow
  • phase iii
  • oxide nanoparticles